Brazil has begun administering a chikungunya vaccine developed and manufactured by the Instituto Butantan to combat the virus's spread [1, 2].
The rollout represents a critical public health response to a severe spike in infections that strained the Brazilian healthcare system last year. By producing the immunizer domestically, Brazil aims to reduce its reliance on foreign medical supplies during outbreaks.
The vaccination campaign began with a pilot program in Mirassol, São Paulo, in early February 2026 [2]. Following the pilot, the state of Minas Gerais began applying the vaccine on Feb. 23, 2026 [1].
These efforts follow a devastating period for public health in the region. In 2025, Brazil recorded approximately 130,000 probable cases of chikungunya and 121 deaths [1]. The virus continued to pose a significant threat into the current year, with more than 8,000 confirmed cases and one confirmed death reported in 2026 [1].
Instituto Butantan is responsible for both the development and the future manufacturing of the vaccine [1, 2]. This vertical integration allows the institute to scale production based on the immediate needs of the national health system.
The deployment in Minas Gerais is part of a broader strategy to curb the transmission of the virus—which is primarily spread by Aedes mosquitoes—before the peak of the rainy season. Local health officials are prioritizing high-risk areas where the 2025 outbreak was most severe [1].
“Brazil recorded approximately 130,000 probable cases of chikungunya and 121 deaths in 2025.”
The transition from a pilot program in São Paulo to a state-wide rollout in Minas Gerais signals Brazil's shift toward a proactive, vaccine-led strategy against arboviruses. By leveraging the Instituto Butantan for both R&D and manufacturing, Brazil is strengthening its health sovereignty and creating a scalable model to address future outbreaks of mosquito-borne diseases without depending on international procurement.
